These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10214745)

  • 1. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD.
    Ichise M; Kim YJ; Ballinger JR; Vines D; Erami SS; Tanaka F; Lang AE
    Neurology; 1999 Apr; 52(6):1206-14. PubMed ID: 10214745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP.
    Kim YJ; Ichise M; Ballinger JR; Vines D; Erami SS; Tatschida T; Lang AE
    Mov Disord; 2002 Mar; 17(2):303-12. PubMed ID: 11921116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.
    Sakakibara R; Shinotoh H; Uchiyama T; Yoshiyama M; Hattori T; Yamanishi T
    J Neurol Sci; 2001 Jun; 187(1-2):55-9. PubMed ID: 11440745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.
    Wenning GK; Donnemiller E; Granata R; Riccabona G; Poewe W
    Mov Disord; 1998 May; 13(3):438-45. PubMed ID: 9613734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease.
    Booij J; Tissingh G; Boer GJ; Speelman JD; Stoof JC; Janssen AG; Wolters EC; van Royen EA
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):133-40. PubMed ID: 9048712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.
    Guttman M; Stewart D; Hussey D; Wilson A; Houle S; Kish S
    Neurology; 2001 Jun; 56(11):1559-64. PubMed ID: 11402115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism.
    Lorberboym M; Djaldetti R; Melamed E; Sadeh M; Lampl Y
    J Nucl Med; 2004 Oct; 45(10):1688-93. PubMed ID: 15471834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia.
    Jeon BS; Jeong JM; Park SS; Kim JM; Chang YS; Song HC; Kim KM; Yoon KY; Lee MC; Lee SB
    Ann Neurol; 1998 Jun; 43(6):792-800. PubMed ID: 9629849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease.
    Ahlskog JE; Uitti RJ; O'Connor MK; Maraganore DM; Matsumoto JY; Stark KF; Turk MF; Burnett OL
    Mov Disord; 1999 Nov; 14(6):940-6. PubMed ID: 10584667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.
    Marek KL; Seibyl JP; Zoghbi SS; Zea-Ponce Y; Baldwin RM; Fussell B; Charney DS; van Dyck C; Hoffer PB; Innis RP
    Neurology; 1996 Jan; 46(1):231-7. PubMed ID: 8559382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.
    Ichise M; Kim YJ; Erami SS; Ballinger JR; Vines D; Tanaka F; Lang AE
    J Nucl Med; 1999 Apr; 40(4):530-8. PubMed ID: 10210210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
    Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
    J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.
    Parkinson Study Group
    JAMA; 2002 Apr; 287(13):1653-61. PubMed ID: 11926889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
    Kim SE; Lee WY; Choe YS; Kim JH
    Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
    Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
    J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
    Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
    Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms.
    Filippi L; Manni C; Pierantozzi M; Brusa L; Danieli R; Stanzione P; Schillaci O
    Nucl Med Commun; 2005 May; 26(5):421-6. PubMed ID: 15838424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.
    Tatsch K; Schwarz J; Mozley PD; Linke R; Pogarell O; Oertel WH; Fieber RS; Hahn K; Kung HF
    Eur J Nucl Med; 1997 Apr; 24(4):415-21. PubMed ID: 9096093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease.
    Booij J; Bergmans P; Winogrodzka A; Speelman JD; Wolters EC
    Synapse; 2001 Feb; 39(2):101-8. PubMed ID: 11180497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.
    Eisensehr I; Linke R; Noachtar S; Schwarz J; Gildehaus FJ; Tatsch K
    Brain; 2000 Jun; 123 ( Pt 6)():1155-60. PubMed ID: 10825354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.